Vitrafy Completes A$30M Placement and Announces SPP
Key points
- A$30M institutional placement completed at A$2.60 per share
- SPP offer to raise up to A$2M for eligible shareholders
- Funds to accelerate US operations and Guardion manufacturing
- Placement supported by new and existing institutional investors
Full summary
Vitrafy Life Sciences Limited has successfully completed a A$30 million institutional placement, receiving firm commitments at a price of A$2.60 per share. The placement was strongly supported by new and existing institutional and sophisticated investors, reflecting confidence in the company's progress in the US blood market. Additionally, Vitrafy will offer a Share Purchase Plan (SPP) to eligible shareholders in Australia and New Zealand to raise up to A$2 million. Proceeds from the placement and SPP will fund the manufacturing of Guardion devices to meet anticipated demand, accelerate US operations, and support general working capital. The SPP will be open for applications from shareholders registered in Australia or New Zealand on the record date, with the offer closing on July 3, 2026.
Guidance
A$30M raised through placement; SPP to raise up to A$2M
Outlook
Vitrafy plans to use the funds to scale Guardion manufacturing, accelerate US operations, and support working capital. The company is confident in its growth opportunities in the US blood market.
Summary generated by a large language model. Please interpret with care.